Skyrizi
Skyrizi ingredients
| Active ingredient | Strength |
|---|---|
| Risankizumab | 180 mg/1.2mL, 600 mg/10mL, 150 mg/mL, 55 mg/.37mL |
What Skyrizi is used for
The FDA lists the approved uses on the official label (below). In the EU, risankizumab is approved as Skyrizi for:
Adult plaque psoriasis Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Psoriatic Arthritis Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Crohn’s disease Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. Ulcerative colitis Skyriz…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Skyrizi
- Generic name
- Risankizumab-rzaa
- Made by
- AbbVie Inc.
- Forms
- Injection, Injection, Solution, Kit
- Given
- Intravenous, Subcutaneous
- Drug class
- Interleukin-23 Antagonist
- FDA approval
- Biologic licence (BLA) BLA761105
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Risankizumab-rzaa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Skyrizi?
Skyrizi (Risankizumab-rzaa) is a specialist medicine made by AbbVie Inc., approved by the US FDA.
What are the ingredients of Skyrizi?
Skyrizi contains Risankizumab (180 mg/1.2mL, 600 mg/10mL, 150 mg/mL, 55 mg/.37mL).
Is Skyrizi approved in Europe?
The same active substance is approved in the EU as Skyrizi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA